The supplemental biologics license application approval is based on findings from the phase 3 innovaTV 301 trial investigating tisotumab vedotin vs investigator’s choice of chemotherapy in cervical cancer.
The FDA accepted the sBLA to convert the accelerated approval of tisotumab vedotin to full approval for patients with recurrent or metastatic cervical cancer whose disease has progressed on or after first-line therapy. The application has also received priority review and has a Prescription Drug User Fee Act target action date of May 9, 2024.1
The approval is based on findings from the phase 3 innovaTV 301 trial, the findings of which were presented at the 2023 European Society of Medical Oncology Congress. Tisotumab demonstrated a 30% reduction in the risk of death compared with investigator’s choice of chemotherapy when used in the second or third line in the intent-to-treat population.
At a median follow-up of 10.8 months (95% CI, 10.3-11.6), the median overall survival (OS) was 11.5 months (95% CI, 9.8-14.9) with tisotumab vs 9.5 months (95% CI, 7.9-10.7) with chemotherapy (HR, 0.70, 95% CI, 0.54-0.89; P = .0038). The 12-month OS rates were 48.7% and 35.3% with tisotumab and chemotherapy, respectively.2
The median progression-free survival (PFS) was 4.2 months (95% CI, 4.0-4.4) with tisotumab vs 2.9 months (95% CI, 2.6-3.1) with chemotherapy (HR, 0.67; 95% CI, 0.54-0.82; P <.0001). The 6-month PFS rates were 30.4% and 18.9% with tisotumab and chemotherapy, respectively.
“The phase 3 innovaTV 301 trial demonstrated a favorable benefit/risk profile, including improvement in overall survival, and adds to the overall data supporting [tisotumab] as a treatment option for people with recurrent and metastatic cervical cancer who have limited treatment options,” said Roger Dansey, MD, chief development officer of oncology at Pfizer, in a press release.1 “The FDA acceptance of our sBLA for review is important progress toward continuing to offer an option that can extend the lives of more adults with cervical cancer.”
Enrollment in the phase 3 innovaTV 301 trial was open to patients who received a diagnosis of recurrent or metastatic cervical cancer, had documented disease progression on or after doublet chemotherapy with or without bevacizumab (Avastin) and an anti–PD(L)1 agent if eligible and available, measurable disease per RECIST v1.1 criteria, an ECOG performance status of 0 or 1, and exposure to no more than 2 prior lines of therapy.2
The study randomized patients 1:1 to receive 2.0 mg/kg of intravenous tisotumab vedotin every 3 weeks (n = 253) or investigator’s choice of chemotherapy (n = 249), which could have included topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed. The primary end point was OS with secondary end points of PFS, ORR, and safety.
“Ultimately, in all cancer care, the word ‘cure’ is something that we don't hear. But if we can get a way to cure some of our patients…if we move forward, we may have that opportunity,” Brian Slomovitz, MD, gynecologic oncologist, director of gynecologic oncology, Mount Sinai Medical Center, Miami Beach, Florida, and primary investigator of the innovaTV 301 trial, said in an interview with Targeted OncologyTM. “But we're seeing that with immunotherapy and in endometrial cancers, we're seeing the word ‘cure.’ We saw that with PARP inhibitors and in BRCA-mutated ovarian cancers, where a percentage of patients are cured.”
“If we could get to a point with recurrent or metastatic cervical cancer, if we can get a portion of those patients cured, it'd be unprecedented,” Slomovitz added.
Avutometinib/Defactinib Leads to Positive Response, Survival Data in Ovarian Cancer
October 18th 2024The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.
Read More